

Kallol Ray Chaudhuri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8528944/publications.pdf>

Version: 2024-02-01

525
papers

33,895
citations

6124

83
h-index

6349

163
g-index

557
all docs

557
docs citations

557
times ranked

20540
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in the Pharmacological and Non-pharmacological Management of Non-motor Symptoms in Parkinson's Disease: An Update Since 2017. <i>Current Neuropharmacology</i> , 2023, 21, 1786-1805.	1.4	8
2	Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation. <i>Journal of Neurology</i> , 2022, 269, 1154-1163.	1.8	63
3	Implications of dopaminergic medication withdrawal in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2022, 129, 1169-1178.	1.4	9
4	Disentangling the PIGD classification for the prediction of cognitive impairment in de novo Parkinson's disease. <i>Journal of Neurology</i> , 2022, 269, 1566-1573.	1.8	4
5	Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians. <i>Movement Disorders</i> , 2022, 37, 182-189.	2.2	18
6	The New Satisfaction with Life and Treatment Scale (SLTS-7) in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 453-464.	1.5	6
7	A Patient-Centered Conceptual Model of Symptoms and Their Impact in Early Parkinson's Disease: A Qualitative Study. <i>Journal of Parkinson's Disease</i> , 2022, 12, 137-151.	1.5	10
8	The neuropsychiatry of Parkinson's disease: advances and challenges. <i>Lancet Neurology</i> , The, 2022, 21, 89-102.	4.9	142
9	Does Ethnicity Influence Recruitment into Clinical Trials of Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2022, 12, 975-981.	1.5	11
10	Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries. <i>BMC Neurology</i> , 2022, 22, 35.	0.8	12
11	Magnetic Resonance Parkinsonism Index Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease. <i>Brain Sciences</i> , 2022, 12, 202.	1.1	3
12	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries. <i>Neurology and Therapy</i> , 2022, 11, 303-318.	1.4	6
13	New approaches to treatments for sleep, pain and autonomic failure in Parkinson's disease - Pharmacological therapies. <i>Neuropharmacology</i> , 2022, 208, 108959.	2.0	7
14	Response to Mylius et al.. <i>Pain</i> , 2022, 163, e495-e495.	2.0	0
15	Wellness, sexual health, and nonmotor Parkinson's. <i>International Review of Neurobiology</i> , 2022, 162, 171-184.	0.9	2
16	The pathophysiology of sexual dysfunction in Parkinson's disease: An overview. <i>International Review of Neurobiology</i> , 2022, 162, 21-34.	0.9	3
17	The impact of nonmotor symptom burden on sexual function. <i>International Review of Neurobiology</i> , 2022, 162, 185-201.	0.9	2
18	Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus. <i>Npj Parkinson's Disease</i> , 2022, 8, 17.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Restricted truncal sagittal movements of rapid eye movement behaviour disorder. <i>Npj Parkinson's Disease</i> , 2022, 8, 26.	2.5	11
20	Ethnic Disparities in Treatment of Chronic Pain in Individuals with Parkinson's Disease Living in the United Kingdom. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 369-374.	0.8	8
21	Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2022, 12, 77-91.	1.2	4
22	Evaluation of the Patient with Parkinson's Disease in the Early Stages: Non-Motor Phase. , 2022, , 18-26.		0
23	The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England. <i>Pharmacoeconomics</i> , 2022, 40, 559-574.	1.7	5
24	Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Tj ETQq0 0 0.8 BT / Overlock 10 T		
25	Parkinson's Disease: An Overview of the Non-Motor Symptomatology. , 2022, , 3-17.		0
26	Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel. <i>Journal of Parkinson's Disease</i> , 2022, 12, 917-926.	1.5	9
27	Coronavirus Disease 2019 and Related Parkinsonism: The Clinical Evidence Thus Far. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 584-593.	0.8	19
28	Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, , 1-12.	1.5	2
29	Self-reported periodontitis and C-reactive protein in Parkinson's disease: a cross-sectional study of two American cohorts. <i>Npj Parkinson's Disease</i> , 2022, 8, 40.	2.5	11
30	Gender gap in deep brain stimulation for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 47.	2.5	22
31	Apomorphine infusion for improving sleep in Parkinson's disease. <i>Lancet Neurology</i> , The, 2022, 21, 395-398.	4.9	4
32	Parkinson's disease and Covid-19: Is there an impact of ethnicity and the need for palliative care. <i>International Review of Neurobiology</i> , 2022, , .	0.9	2
33	Diagnostic accuracy of keystroke dynamics as digital biomarkers for fine motor decline in neuropsychiatric disorders: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2022, 12, 7690.	1.6	30
34	Relevance of sleep and associated structural changes in GBA1 mouse to human rapid eye movement behavior disorder. <i>Scientific Reports</i> , 2022, 12, 7973.	1.6	9
35	Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2022, , 1.	1.4	3
36	Frailty in Parkinson's disease and its association with early dementia: A longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2022, 99, 51-57.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness analysis of the Parkinson's KineticGraph and clinical assessment in the management of Parkinson's disease. <i>Journal of Medical Economics</i> , 2022, 25, 774-782.	1.0	5
38	Treatment paradigms in Parkinson's Disease and Covid-19. <i>International Review of Neurobiology</i> , 2022, , .	0.9	1
39	239â€¦ New de novo mutation in CACNA1a gene leading to episodic ataxia type 2. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A82.3-A82.	0.9	0
40	Spotlight on non-motor symptoms and Covid-19. <i>International Review of Neurobiology</i> , 2022, , .	0.9	0
41	The Impact of a Digital Artificial Intelligence System on the Monitoring and Self-management of Nonmotor Symptoms in People With Parkinson Disease: Proposal for a Phase 1 Implementation Study. <i>JMIR Research Protocols</i> , 2022, 11, e40317.	0.5	1
42	Movement disorders in COVID-19 times: impact on care in movement disorders and Parkinson disease. <i>Current Opinion in Neurology</i> , 2022, 35, 494-501.	1.8	5
43	Characterization of Non-Motor Fluctuations Using the Movement Disorder Society <scp>Non-Motor</scp> Rating Scale. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 932-940.	0.8	5
44	Multimodal analysis of gene expression from postmortem brains and blood identifies synaptic vesicle trafficking genes to be associated with Parkinson's disease. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	20
45	Emotional well-being and pain could be a greater determinant of quality of life compared to motor severity in cervical dystonia. <i>Journal of Neural Transmission</i> , 2021, 128, 305-314.	1.4	11
46	Progression of sleep disturbances in Parkinson's disease: a 5-year longitudinal study. <i>Journal of Neurology</i> , 2021, 268, 312-320.	1.8	30
47	Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the <scp>MDSâ€NMS</scp>. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 231-239.	0.8	35
48	Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. <i>Journal of Parkinson's Disease</i> , 2021, 11, 299-307.	1.5	15
49	Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated âœBiphasicâ€Dyskinesia with Pallidal Deep Brain Stimulation. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 273-274.	0.8	7
50	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 146-149.	1.1	7
51	Subthalamic Stimulation Improves Quality of Sleep in Parkinson Disease: A 36-Month Controlled Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 323-335.	1.5	21
52	The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 3-12.	1.0	49
53	Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: An Explorative Study. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 1-9.	1.4	12
54	Assessment of real life eating difficulties in Parkinson's disease patients by measuring plate to mouth movement elongation with inertial sensors. <i>Scientific Reports</i> , 2021, 11, 1632.	1.6	19

#	ARTICLE	IF	CITATIONS
55	Dysregulation of epithelial ion transport and neurochemical changes in the colon of a parkinsonian primate. <i>Npj Parkinson's Disease</i> , 2021, 7, 9.	2.5	4
56	Rotigotine Transdermal Patch for Motor and Non-motor Parkinsonâ€™s Disease: A Review of 12 Yearsâ€™ Clinical Experience. <i>CNS Drugs</i> , 2021, 35, 215-231.	2.7	24
57	Non-motor complications in late stage Parkinsonâ€™s disease: recognition, management and unmet needs. Expert Review of Neurotherapeutics, 2021, 21, 335-352.	1.4	20
58	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 79-85.	1.1	39
59	Two heterozygous progranulin mutations in progressive supranuclear palsy. <i>Brain</i> , 2021, 144, e27-e27.	3.7	9
60	Pain in Parkinson's disease: Mechanism-based treatment strategies. <i>Current Opinion in Supportive and Palliative Care</i> , 2021, 15, 108-115.	0.5	11
61	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinsonâ€™s disease. <i>Brain and Behavior</i> , 2021, 11, e02086.	1.0	6
62	How Time Rules: Diurnal Motor Patterns in de novo Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 695-702.	1.5	14
63	The role of gut dysbiosis in Parkinsonâ€™s disease: mechanistic insights and therapeutic options. <i>Brain</i> , 2021, 144, 2571-2593.	3.7	119
64	Cost-Effectiveness of Device-Aided Therapies in Parkinsonâ€™s Disease: A Structured Review. <i>Journal of Parkinson's Disease</i> , 2021, 11, 475-489.	1.5	11
65	Reply to Comment on: Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated â€œBiphasicâ€œ-Likeâ€œ-Dyskinesia with Pallidal Deep Brain Stimulation. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 814-815.	0.8	0
66	Parkinson's Disease and <sc>Postâ€œCOVID</sc>â€œ19 Syndrome: The Parkinson's <sc>Longâ€œCOVID</sc> Spectrum. <i>Movement Disorders</i> , 2021, 36, 1287-1289.	2.2	51
67	The impact of COVID-19 on palliative care for people with Parkinsonâ€™s and response to future pandemics. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 615-623.	1.4	15
68	REPRINTED WITH PERMISSION OF IASP â€œ PAIN 162 (2021) 999â€œ1006: Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease. <i>BÃl</i> , 2021, 22, 46-55.	0.1	0
69	Cross-sectional analysis of the Parkinsonâ€™s disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. <i>Scientific Reports</i> , 2021, 11, 9611.	1.6	21
70	The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on â€œOffâ€œ-time in Patients with Advanced Parkinsonâ€™s Disease: A Systematic Review. <i>Advances in Therapy</i> , 2021, 38, 2854-2890.	1.3	41
71	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 48.	2.5	23
72	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	18.1	391

#	ARTICLE	IF	CITATIONS
73	Parkinsonâ€™s Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors. <i>Journal of Personalized Medicine</i> , 2021, 11, 680.	1.1	6
74	Reply to: Subthalamic Nucleus Deep Brain Stimulation as Rescue Therapy for Levodopa Carbidopa Intestinal Gelâ€™Associated Biphasicâ€™Like Dyskinesias. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1157-1158.	0.8	0
75	Functional Neurological Disorders and <scp>COVIDâ€™19</scp> Vaccination. <i>Annals of Neurology</i> , 2021, 90, 328-328.	2.8	6
76	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. <i>Parkinsonism and Related Disorders</i> , 2021, 89, 186-194.	1.1	26
77	Personalised Advanced Therapies in Parkinsonâ€™s Disease: The Role of Non-Motor Symptoms Profile. <i>Journal of Personalized Medicine</i> , 2021, 11, 773.	1.1	20
78	Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregiversâ€™Study Protocol for a Multicentre, Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2021, 12, 673893.	1.1	7
79	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinsonâ€™s Disease: A Longitudinal Analysis of Two International Cohorts. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1209-1219.	1.5	29
80	Evaluation of the effect of bilateral subthalamic nucleus deep brain stimulation on fatigue in Parkinsonâ€™s Disease as measured by the non-motor symptoms scale. <i>British Journal of Neurosurgery</i> , 2021, , 1-4.	0.4	7
81	Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 52-56.	1.1	4
82	Early Factors for Predicting Discontinuation to Subcutaneous Apomorphine Infusion in Parkinsonâ€™s disease: A Prospective Analysis of the Thai Apomorphine Registry. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 146-151.	1.1	6
83	Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1313-1318.	0.9	12
84	Effects of safinamide on pain in patients with fluctuating Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e2336.	1.0	18
85	<scp>DUOGLOBE</scp>: Oneâ€™Year Outcomes in a <scp>Realâ€™World</scp> Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1061-1074.	0.8	22
86	Neurogenic and anti-inflammatory effects of probiotics in Parkinsonâ€™s disease: A systematic review of preclinical and clinical evidence. <i>Brain, Behavior, and Immunity</i> , 2021, 98, 59-73.	2.0	35
87	Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease. <i>International Journal of Pharmaceutics: X</i> , 2021, 3, 100087.	1.2	19
88	Thirty years of research on autonomic dysfunction, non-motor features, and endophenotypes in Parkinson disease. <i>Clinical Autonomic Research</i> , 2021, 31, 37-39.	1.4	6
89	General approach to patients with autonomic dysfunction in Parkinson's disease. <i>International Review of Movement Disorders</i> , 2021, 1, 19-39.	0.1	2
90	The Parkinson disease pain classification system: results from an international mechanism-based classification approach. <i>Pain</i> , 2021, 162, 1201-1210.	2.0	40

#	ARTICLE	IF	CITATIONS
91	Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease. <i>Pain</i> , 2021, 162, 999-1006.	2.0	23
92	Scaling-up Health-Arts Programmes: the largest study in the world bringing arts-based mental health interventions into a national health service. <i>BJPsych Bulletin</i> , 2021, 45, 32-39.	0.7	18
93	Disease severity in the DUOGLOBE patient population based on manage-PD section 2 domains: Interim subgroup analysis. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119575.	0.3	0
94	on Management of Pain in Parkinsonâ€™s. <i>NeuroMethods</i> , 2021, , 293-321.	0.2	0
95	Mind the gap: Inequalities in mental health care and lack of social support in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2021, 93, 97-102.	1.1	13
96	Periodic limb movements during sleep: a narrative review. <i>Journal of Thoracic Disease</i> , 2021, 13, 6476-6494.	0.6	11
97	Pain in neurodegenerative diseases with atypical parkinsonis a systematic review on prevalence, clinical presentation, and findings from experimental studies. <i>Journal of Integrative Neuroscience</i> , 2021, 20, 1067-1078.	0.8	4
98	Identifying Parkinsonâ€™s disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. <i>Scientific Reports</i> , 2021, 11, 23645.	1.6	11
99	The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study. <i>Movement Disorders</i> , 2020, 35, 116-133.	2.2	59
100	Beneficial nonmotor effects of subthalamic and pallidal neurostimulation in Parkinsonâ€™s disease. <i>Brain Stimulation</i> , 2020, 13, 1697-1705.	0.7	36
101	Neurological research & training after the easing of lockdown in countries impacted by COVID-19. <i>Journal of the Neurological Sciences</i> , 2020, 418, 117105.	0.3	3
102	A Dual Centre Study of Pain in Parkinsonâ€™s Disease and Its Relationship with Other Non-Motor Symptoms. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1817-1825.	1.5	17
103	The association between pain and impulse control behaviours in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 53-55.	1.1	3
104	Therapy of Parkinson's Disease Subtypes. <i>Neurotherapeutics</i> , 2020, 17, 1366-1377.	2.1	42
105	â€ˆDopamine agonist Phobiaâ€™ in Parkinsonâ€™s disease: when does it matter? Implications for non-motor symptoms and personalized medicine. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 953-965.	1.4	7
106	Reply to: â€œConcerns Raised by Publication of Antonini et al., â€ˆOutcome of Parkinson Disease Patients Affected by Covidâ€™19â€™. <i>Movement Disorders</i> , 2020, 35, 1298-1298.	2.2	3
107	Screening of Parkinsonian subtle fine-motor impairment from touchscreen typing via deep learning. <i>Scientific Reports</i> , 2020, 10, 12623.	1.6	22
108	Application of the â€ˆ5-2-1â€™ screening criteria in advanced Parkinsonâ€™s disease: interim analysis of DUOGLOBE. <i>Neurodegenerative Disease Management</i> , 2020, 10, 309-323.	1.2	33

#	ARTICLE	IF	CITATIONS
109	Effect of Short-term Integrated Palliative Care on Patient-Reported Outcomes Among Patients Severely Affected With Long-term Neurological Conditions. <i>JAMA Network Open</i> , 2020, 3, e2015061.	2.8	26
110	COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. <i>Npj Parkinson's Disease</i> , 2020, 6, 18.	2.5	120
111	Unobtrusive detection of Parkinson's disease from multi-modal and in-the-wild sensor data using deep learning techniques. <i>Scientific Reports</i> , 2020, 10, 21370.	1.6	32
112	A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey. <i>Frontiers in Psychiatry</i> , 2020, 11, 602480.	1.3	1
113	Unmet needs in Parkinson disease: Motor and non-motor. <i>Parkinsonism and Related Disorders</i> , 2020, 80, S7-S12.	1.1	56
114	Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies. <i>CNS Drugs</i> , 2020, 34, 1149-1163.	2.7	25
115	A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 687-694.	0.9	36
116	Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint. <i>Frontiers in Neurology</i> , 2020, 11, 556.	1.1	28
117	Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey. <i>Journal of Neural Transmission</i> , 2020, 127, 875-879.	1.4	10
118	Stress and cortisol in Parkinson's disease. <i>International Review of Neurobiology</i> , 2020, 152, 131-156.	0.9	18
119	Dyskinesia Matters: But Not as Much as It Used to. <i>Movement Disorders</i> , 2020, 35, 900-901.	2.2	2
120	Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson's disease. <i>Journal of Neurology</i> , 2020, 267, 1830-1841.	1.8	17
121	Factor Analysis and Clustering of the Movement Disorder Society's "Non-Motor Rating Scale. <i>Movement Disorders</i> , 2020, 35, 969-975.	2.2	9
122	Drooling in Parkinson's Disease: Prevalence and Progression from the Non-motor International Longitudinal Study. <i>Dysphagia</i> , 2020, 35, 955-961.	1.0	51
123	The clinical impact of COVID-19 infection on people with Parkinson's. <i>British Journal of Neuroscience Nursing</i> , 2020, 16, 121-124.	0.1	1
124	Opicapone and Levodopa-Carbidopa Intestinal Gel Infusion: The Way Forward Towards Cost Savings for Healthcare Systems?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1535-1539.	1.5	19
125	Genome-Wide Association Study of Pain in Parkinson's Disease Implicates <i>TRPM8</i> as a Risk Factor. <i>Movement Disorders</i> , 2020, 35, 705-707.	2.2	7
126	Impulse control and related behaviors in Parkinson's disease with dementia. <i>European Journal of Neurology</i> , 2020, 27, 944-950.	1.7	15

#	ARTICLE	IF	CITATIONS
127	Dementia in long-term Parkinsonâ€™s disease patients: a multicentre retrospective study. Npj Parkinson's Disease, 2020, 6, 2.	2.5	32
128	Keep calm and beam on? Unmet needs in radiotherapy and deep brain stimulation. Parkinsonism and Related Disorders, 2020, 71, 15-16.	1.1	0
129	Potential of animal models for advancing the understanding and treatment of pain in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 1.	2.5	81
130	Outcome of Parkinson's Disease Patients Affected by COVID-19. Movement Disorders, 2020, 35, 905-908.	2.2	192
131	Identifying and responding to fatigue and apathy in Parkinsonâ€™s disease: a review of current practice. Expert Review of Neurotherapeutics, 2020, 20, 477-495.	1.4	29
132	Editorial: Prodromal Parkinson's Disease. Frontiers in Neurology, 2020, 11, 634490.	1.1	2
133	Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinsonâ€™s disease management in developing countries. Expert Review of Neurotherapeutics, 2020, 20, 523-537.	1.4	7
134	Serum Uric Acid Levels and Non-Motor Symptoms in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1003-1010.	1.5	17
135	Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1087-1098.	1.5	46
136	Immediate versus delayed short-term integrated palliative care for advanced long-term neurological conditions: the OPTCARE Neuro RCT. Health Services and Delivery Research, 2020, 8, 1-80.	1.4	4
137	Non-motor symptoms in cervical dystonia: A concept in evolution. Annals of Indian Academy of Neurology, 2020, 23, 428.	0.2	2
138	Beneficial effects of bilateral subthalamic stimulation on alexithymia in Parkinson's disease. European Journal of Neurology, 2019, 26, 222.	1.7	22
139	Can therapeutic strategies prevent and manage dyskinesia in Parkinsonâ€™s disease? An update. Expert Opinion on Drug Safety, 2019, 18, 1203-1218.	1.0	29
140	Editorial: Movement Disorders and Sleep â€“ Underlying Mechanisms, Clinical Aspects and Treatment. Frontiers in Neurology, 2019, 10, 1034.	1.1	2
141	Non-motor correlates of wrist-worn wearable sensor use in Parkinsonâ€™s disease: an exploratory analysis. Npj Parkinson's Disease, 2019, 5, 22.	2.5	21
142	Acupuncture Effect and Mechanism for Treating Pain in Patients With Parkinson's Disease. Frontiers in Neurology, 2019, 10, 1114.	1.1	39
143	Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinsonâ€™s disease. BMC Neuroscience, 2019, 20, 55.	0.8	9
144	Restless legs syndrome - the under-recognised non-motor burden: a questionnaire-based cohort study. Postgraduate Medicine, 2019, 131, 473-478.	0.9	6

#	ARTICLE	IF	CITATIONS
145	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019, 142, 3592-3604.	3.7	90
146	Pilot Study of the International Parkinson and Movement Disorder Society's sponsored Non-motor Rating Scale (MDS-UOMS). <i>Movement Disorders Clinical Practice</i> , 2019, 6, 227-234.	0.8	31
147	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 353-365.	2.2	126
148	Contractile dysfunction and nitroergic dysregulation in small intestine of a primate model of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2019, 5, 10.	2.5	13
149	Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 1736-1742.	1.8	27
150	Extensive validation study of the Parkinson's Disease Composite Scale. <i>European Journal of Neurology</i> , 2019, 26, 1281-1288.	1.7	8
151	Barriers to reporting non-motor symptoms to health-care providers in people with Parkinson's. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 220-225.	1.1	32
152	Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?. <i>Movement Disorders</i> , 2019, 34, 816-819.	2.2	47
153	Slave to the rhythm: Seasonal differences in non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 73-76.	1.1	14
154	Applications of the European Parkinson's Disease Association sponsored Parkinson's Disease Composite Scale (PDCS). <i>Npj Parkinson's Disease</i> , 2019, 5, 26.	2.5	6
155	Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens". <i>Movement Disorders</i> , 2019, 34, 1930-1931.	2.2	2
156	Pain in Parkinson's disease: new concepts in pathogenesis and treatment. <i>Current Opinion in Neurology</i> , 2019, 32, 579-588.	1.8	61
157	Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. <i>Neurodegenerative Disease Management</i> , 2019, 9, 39-46.	1.2	19
158	Update on treatments for nonmotor symptoms of Parkinson's disease: an evidence-based medicine review. <i>Movement Disorders</i> , 2019, 34, 180-198.	2.2	619
159	Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 57-64.	0.8	17
160	Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel. <i>European Journal of Neurology</i> , 2019, 26, 581.	1.7	23
161	Amyloid- β and Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 2605-2619.	1.8	79
162	Evaluation of nocturnal hypokinesia in Parkinson's disease using a novel patient/proxy questionnaire and correlations with objective monitoring. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 219-223.	1.1	10

#	ARTICLE	IF	CITATIONS
163	Identifying barriers to help-seeking for non-motor symptoms in people with Parkinson's disease. <i>Journal of Health Psychology</i> , 2019, 24, 561-571.	1.3	12
164	Societal Burden and Persisting Unmet Needs of Parkinson's Disease. <i>European Neurological Review</i> , 2019, 14, 28.	0.5	13
165	Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018, 18, 630-637.	1.4	52
166	Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 421-430.	2.2	69
167	Pain in Parkinson's disease: facts and uncertainties. <i>European Journal of Neurology</i> , 2018, 25, 917.	1.7	66
168	Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease. <i>Brain Stimulation</i> , 2018, 11, 867-874.	0.7	36
169	Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts. <i>Brain Stimulation</i> , 2018, 11, 904-912.	0.7	53
170	Comprehensive grading of Parkinson's disease using motor and non-motor assessments: addressing a key unmet need. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 41-50.	1.4	30
171	Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2018, 25, 307-312.	1.7	21
172	The Parkinson's Disease Composite Scale: results of the first validation study. <i>European Journal of Neurology</i> , 2018, 25, 503-511.	1.7	18
173	Quality of life outcome after subthalamic stimulation in Parkinson's disease depends on age. <i>Movement Disorders</i> , 2018, 33, 99-107.	2.2	39
174	A study investigating the experience of working for people with Parkinson's and the factors that influence workplace success. <i>Disability and Rehabilitation</i> , 2018, 40, 2032-2039.	0.9	8
175	Dietary Variations in a Multiethnic Parkinson's Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study. <i>Parkinson's Disease</i> , 2018, 2018, 1-9.	0.6	4
176	Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease. <i>Chinese Medical Journal</i> , 2018, 131, 2976-2985.	0.9	24
177	Motor Impairment Estimates via Touchscreen Typing Dynamics Toward Parkinson's Disease Detection From Data Harvested In-the-Wild. <i>Frontiers in ICT</i> , 2018, 5, .	3.6	25
178	Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, S65-S72.	1.5	32
179	Levodopa Phobia: a review of a not uncommon and consequential phenomenon. <i>Npj Parkinson's Disease</i> , 2018, 4, 31.	2.5	28
180	First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire. <i>European Journal of Neurology</i> , 2018, 25, 1255-1261.	1.7	25

#	ARTICLE	IF	CITATIONS
181	Changes in Parkinson's disease sleep symptoms and daytime somnolence after bilateral subthalamic deep brain stimulation in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 16.	2.5	14
182	Motor and nonmotor complications of levodopa: Phenomenology, risk factors, and imaging features. <i>Movement Disorders</i> , 2018, 33, 909-919.	2.2	89
183	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2018, 17, 749-759.	4.9	203
184	Exploring Bedroom Usability and Accessibility in Parkinson's Disease (PD): The Utility of a PD Home Safety Questionnaire and Implications for Adaptations. <i>Frontiers in Neurology</i> , 2018, 9, 360.	1.1	5
185	Noninvasive options for "wearing-off" in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists. <i>Neurodegenerative Disease Management</i> , 2018, 8, 349-360.	1.2	22
186	Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease. <i>CNS Drugs</i> , 2018, 32, 621-635.	2.7	43
187	Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2018, 4, 14.	2.5	70
188	A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 27-32.	1.1	77
189	Non-motor Parkinson disease: new concepts and personalised management. <i>Medical Journal of Australia</i> , 2018, 208, 404-409.	0.8	77
190	Impact of ethnicity on the natural history of Parkinson disease. <i>Medical Journal of Australia</i> , 2018, 208, 410-414.	0.8	28
191	A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 937-945.	0.9	7
192	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 81-95.	4.9	252
193	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 217-231.	4.9	705
194	Urinary dysfunction in early de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 939-940.	2.2	9
195	Distribution and impact on quality of life of the pain modalities assessed by the King's Parkinson's disease pain scale. <i>Npj Parkinson's Disease</i> , 2017, 3, 8.	2.5	27
196	Intrajejunal levodopa infusion therapy for Parkinson's disease: practical and pragmatic tips for successful maintenance of therapy. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 529-537.	1.4	3
197	Treatment of Nonmotor Symptoms in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 361-379.	0.9	15
198	Biomarkers of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 183-196.	0.9	18

#	ARTICLE	IF	CITATIONS
199	A new tool to identify patients with Parkinson's disease at increased risk of dementia. <i>Lancet Neurology</i> , 2017, 16, 576-578.	4.9	7
200	Preface. <i>International Review of Neurobiology</i> , 2017, 132, xv.	0.9	0
201	Non-motor features of Parkinson disease. <i>Nature Reviews Neuroscience</i> , 2017, 18, 435-450.	4.9	1,182
202	Personalized medicine in Parkinson's disease: Time to be precise. <i>Movement Disorders</i> , 2017, 32, 1147-1154.	2.2	123
203	The Nonmotor Features of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 33-54.	0.9	56
204	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 325-331.	0.9	78
205	Parkinsonâ€™s: a syndrome rather than a disease?. <i>Journal of Neural Transmission</i> , 2017, 124, 907-914.	1.4	168
206	Clinical Determinants of Parkinson's Diseaseâ€™associated Pain Using the King's Parkinson's Disease Pain Scale. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 545-551.	0.8	27
207	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 13-20.	1.1	149
208	Palliative Care and Nonmotor Symptoms in Parkinson's Disease and Parkinsonism. <i>International Review of Neurobiology</i> , 2017, 134, 1239-1255.	0.9	7
209	Nonmotor Parkinson's and Future Directions. <i>International Review of Neurobiology</i> , 2017, 134, 1493-1505.	0.9	17
210	Letter to the editor: Automated night-time deep brain stimulation battery checks can induce symptoms: Identification and management of a new hardware complication. <i>Brain Stimulation</i> , 2017, 10, 1148-1149.	0.7	0
211	Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations. <i>Neuroepidemiology</i> , 2017, 49, 1-17.	1.1	29
212	Nonmotor Symptoms in Experimental Models of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 63-89.	0.9	24
213	The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinsonâ€™s disease. <i>Journal of Medical Economics</i> , 2017, 20, 1207-1215.	1.0	22
214	Personalized Medicine and Nonmotor Symptoms in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 134, 1257-1281.	0.9	42
215	Rotigotine transdermal patch and sleep in Parkinsonâ€™s disease: where are we now?. <i>Npj Parkinson's Disease</i> , 2017, 3, 28.	2.5	14
216	Nonmotor Subtyping in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 447-478.	0.9	18

#	ARTICLE	IF	CITATIONS
217	Depression and Catechol-O-methyltransferase (COMT) genetic variants are associated with pain in Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 6306.	1.6	41
218	Palliative Care for Patients and Families With Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 475-509.	0.9	13
219	Two hundred years since James Parkinson's essay on the shaking palsy—Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017. <i>Movement Disorders</i> , 2017, 32, 1311-1315.	2.2	7
220	Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed. <i>Journal of Neural Transmission</i> , 2017, 124, 1529-1537.	1.4	46
221	Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?. <i>Npj Parkinson's Disease</i> , 2017, 3, 5.	2.5	29
222	Using a smartphone-based self-management platform to support medication adherence and clinical consultation in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2017, 3, 2.	2.5	63
223	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. <i>Movement Disorders</i> , 2017, 32, 235-240.	2.2	18
224	Self-Assessment of Disability in Parkinson's Disease: The MDS-UPDRS Part II Versus Clinician-Based Ratings. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 529-535.	0.8	14
225	Non motor symptoms in progressive supranuclear palsy: prevalence and severity. <i>Npj Parkinson's Disease</i> , 2017, 3, 35.	2.5	29
226	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. <i>Journal of Parkinson's Disease</i> , 2017, 7, 533-543.	1.5	45
227	Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition. <i>Parkinson's Disease</i> , 2017, 2017, 1-18.	0.6	29
228	Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia. <i>PLoS ONE</i> , 2017, 12, e0175797.	1.1	12
229	The Future of Parkinson's Treatment — Personalised and Precision Medicine. <i>European Neurological Review</i> , 2017, 12, 15.	0.5	7
230	Surgical Treatment of Parkinson's Disease, Transplantations and Restorative Therapies for Parkinson's Diseases. , 2017, , 157-164.		0
231	The Non-motor Parkinson's Disease. , 2017, , 117-127.		0
232	Non-Motor Symptoms in Patients Suffering from Motor Neuron Diseases. <i>Frontiers in Neurology</i> , 2016, 7, 117.	1.1	43
233	Psychometric Properties of a Generic, Patient-Centred Palliative Care Outcome Measure of Symptom Burden for People with Progressive Long Term Neurological Conditions. <i>PLoS ONE</i> , 2016, 11, e0165379.	1.1	19
234	Progression of nonmotor symptoms in subgroups of patients with non-dopamine-deficient Parkinsonism. <i>Movement Disorders</i> , 2016, 31, 344-351.	2.2	23

#	ARTICLE	IF	CITATIONS
235	Nonmotor features of Parkinson's disease subtypes. <i>Movement Disorders</i> , 2016, 31, 1095-1102.	2.2	254
236	A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 852-861.	1.0	79
237	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , 2016, 23, 1255-1261.	1.7	76
238	Improvement of dyskinesias with L-DOPA infusion in advanced Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 451-458.	1.0	23
239	Night-time sleep in Parkinson's disease – the potential use of Parkinson's KinetiGraph: a prospective comparative study. <i>European Journal of Neurology</i> , 2016, 23, 1275-1288.	1.7	38
240	CME Movement disorders (100624): self-assessment questionnaire. <i>Clinical Medicine</i> , 2016, 16, 390-391.	0.8	0
241	Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson's disease. , 2016, , 48-62.		7
242	Unmet needs in Parkinson's disease: New horizons in a changing landscape. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S2-S8.	1.1	19
243	Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the future. <i>Npj Parkinson's Disease</i> , 2016, 2, 16023.	2.5	43
244	Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S36-S41.	1.1	27
245	The efficacy of apomorphine – A non-motor perspective. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S28-S35.	1.1	30
246	Apomorphine therapy in Parkinson's disease and future directions. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S56-S60.	1.1	22
247	Analysis of four scales for global severity evaluation in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016, 2, 16007.	2.5	27
248	Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therapy. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S49-S55.	1.1	31
249	Progression and biomarkers for Parkinson disease. <i>Neurology</i> , 2016, 87, 128-129.	1.5	5
250	How integrated are neurology and palliative care services? Results of a multicentre mapping exercise. <i>BMC Neurology</i> , 2016, 16, 63.	0.8	41
251	New concepts in the pathogenesis and presentation of Parkinson's disease. <i>Clinical Medicine</i> , 2016, 16, 365-370.	0.8	47
252	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>European Journal of Neurology</i> , 2016, 23, 1556-1565.	1.7	51

#	ARTICLE	IF	CITATIONS
253	Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 527-537.	0.8	46
254	Anatomical and functional correlates of persistent pain in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1854-1864.	2.2	57
255	Parkinson's Impulseâ€Control Scale for the Severity Rating of Impulseâ€Control Behaviors in Parkinson's Disease: A Semistructured Clinical Assessment Tool. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 494-499.	0.8	25
256	Clinically relevant cut-off values for the Parkinson's Disease Sleep Scale-2 (PDSS-2): a validation study. <i>Sleep Medicine</i> , 2016, 24, 87-92.	0.8	41
257	Practice guideline summary: Treatment of restless legs syndrome in adults. <i>Neurology</i> , 2016, 87, 2585-2593.	1.5	182
258	The treatment challenges of restless legs syndrome. <i>The Prescriber</i> , 2016, 27, 15-21.	0.1	0
259	Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease. <i>Neurology</i> , 2016, 87, 2451-2456.	1.5	32
260	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 270-279.	2.2	55
261	Levodopa-carbidopa intestinal gel treatment in patients with < 10 years of Parkinson's disease: GLORIA registry interim results. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e93-e94.	1.1	0
262	The First Parkinson's Disease Pain Questionnaire (King's PD Pain Quest) â€“ an interim analysis of a multicentre study of the patient's perspective. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e41.	1.1	3
263	Dysphagia, pneumonia and hospital admissions in Parkinson's Disease: a multicentre observational study. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e47-e48.	1.1	0
264	PANDA: Prolonged release oxycodone/naloxone (OXN PR) for severe Parkinsonâ€™s disease (PD)-related pain. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e101-e102.	1.1	0
265	Unravelling the nonmotor mysteries of Parkinson disease. <i>Nature Reviews Neurology</i> , 2016, 12, 10-11.	4.9	28
266	Non motor subtypes and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S41-S46.	1.1	268
267	Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease. <i>Brain Stimulation</i> , 2016, 9, 78-85.	0.7	86
268	New clinical trials for nonmotor manifestations of Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1490-1504.	2.2	81
269	Nonâ€motor symptoms burden in treated and untreated early Parkinson's disease patients: argument for nonâ€motor subtypes. <i>European Journal of Neurology</i> , 2015, 22, 1145-1150.	1.7	64
270	The range and nature of non-motor symptoms in drug-naive Parkinsonâ€™s disease patients: a state-of-the-art systematic review. <i>Npj Parkinson's Disease</i> , 2015, 1, 15013.	2.5	67

#	ARTICLE	IF	CITATIONS
271	Intraindividual Variability of Nonmotor Fluctuations in Advanced Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 737-741.	1.5	11
272	Restless Legs Syndrome: briefing. <i>British Journal of Neuroscience Nursing</i> , 2015, 11, 290-292.	0.1	1
273	King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. <i>Movement Disorders</i> , 2015, 30, 1623-1631.	2.2	189
274	A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 170-174.	0.8	19
275	Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms – results of a double-blind, randomized, placebo-controlled trial. <i>European Journal of Neurology</i> , 2015, 22, 1400-1407.	1.7	66
276	Effective Delivery of Apomorphine in the Management of Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2015, 38, 89-103.	0.2	48
277	Infusion Therapies and Development of Impulse Control Disorders in Advanced Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2015, 38, 132-134.	0.2	52
278	Thinking about motor fluctuations: An examination of metacognitions in Parkinson's disease. <i>Journal of Psychosomatic Research</i> , 2015, 79, 669-673.	1.2	19
279	Small fiber neuropathy in Parkinson's disease: A clinical, pathological and corneal confocal microscopy study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1454-1460.	1.1	117
280	Euro-Multicenter Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease. <i>Movement Disorders</i> , 2015, 30, 510-516.	2.2	203
281	Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. <i>European Journal of Neurology</i> , 2015, 22, 37-43.	1.7	82
282	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015, 30, 150-159.	2.2	92
283	Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 373-378.	2.2	41
284	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1133-1144.	1.1	156
285	Psychosis in Parkinson's Disease. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2015, , 113-139.	0.3	1
286	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 287-291.	1.1	93
287	Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 629-634.	1.1	166
288	Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 1161-1170.	4.9	102

#	ARTICLE	IF	CITATIONS
289	Impulse control dysfunction and dopamine agonist withdrawal syndrome in Genetic Parkinson's: A case report. <i>Basal Ganglia</i> , 2015, 5, 57-58.	0.3	5
290	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1023-1030.	1.1	126
291	Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS). <i>Journal of Neural Transmission</i> , 2015, 122, 1673-1684.	1.4	52
292	Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 50-54.	1.1	216
293	Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. <i>Alzheimer's and Dementia</i> , 2015, 11, 608.	0.4	161
294	Twenty Years of Apomorphine Therapy – How Does it Compare with Levodopa?. <i>European Neurological Review</i> , 2015, 9, 113.	0.5	1
295	Extending our Understanding of the Dopaminergic Basis of Non-motor Symptoms in Parkinson's Disease. <i>European Neurological Review</i> , 2015, 10, 23.	0.5	2
296	Diffusion Tensor Imaging of Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy: A Tract-Based Spatial Statistics Study. <i>PLoS ONE</i> , 2014, 9, e112638.	1.1	72
297	Non-Motor Symptoms Profile and Burden in Drug Naïve Versus Long-Term Parkinson's Disease Patients. <i>Journal of Parkinson's Disease</i> , 2014, 4, 541-547.	1.5	41
298	Nonmotor symptoms and focal cervical dystonia: Observations from 102 patients. <i>Basal Ganglia</i> , 2014, 4, 117-120.	0.3	37
299	How Do I Examine Nonmotor Aspects of Parkinson's Disease? What Not to Miss and What to Ignore?. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 274-274.	0.8	1
300	A review of current treatment strategies for restless legs syndrome (Willis-Ekbom disease). <i>Clinical Medicine</i> , 2014, 14, 520-524.	0.8	18
301	Smartphone- and internet-assisted self-management and adherence tools to manage Parkinson's disease (SMART-PD): study protocol for a randomised controlled trial (v7; 15 August 2014). <i>Trials</i> , 2014, 15, 374.	0.7	29
302	The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 106-116.	1.8	70
303	Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD). <i>Health and Quality of Life Outcomes</i> , 2014, 12, 11.	1.0	41
304	Associations between Severity of Motor Function and Nonmotor Symptoms in Parkinson's Disease: A Post Hoc Analysis of the RECOVER Study. <i>European Neurology</i> , 2014, 71, 140-147.	0.6	16
305	Unexplained lower limb pain in Parkinson's disease: A phenotypic variant of "painful Parkinson's disease". <i>Parkinsonism and Related Disorders</i> , 2014, 20, 122-124.	1.1	21
306	Therapeutic options for nocturnal problems in Parkinson's disease and atypical parkinsonian disorders. <i>Journal of Neural Transmission</i> , 2014, 121, 25-31.	1.4	7

#	ARTICLE	IF	CITATIONS
307	Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 148-152.	0.9	77
308	Non-motor symptoms of Parkinson's disease A review from the past. <i>Journal of the Neurological Sciences</i> , 2014, 338, 30-33.	0.3	93
309	Guide to Assessment Scales in Parkinson's Disease. , 2014, , .		5
310	Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: An international multicenter study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1231-1235.	1.1	76
311	Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. <i>Practical Neurology</i> , 2014, 14, 310-322.	0.5	167
312	Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study. <i>BMC Neurology</i> , 2014, 14, 42.	0.8	53
313	Vanishing White Matter Disease Presenting as Opsoclonus Myoclonus Syndrome in Childhood? A Case Report and Review of the Literature. <i>Pediatric Neurology</i> , 2014, 51, 157-164.	1.0	7
314	An Update of the Impact of Deep Brain Stimulation on Non Motor Symptoms in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 289-300.	1.5	29
315	Review of Quality of Life Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1351-1357.	1.4	25
316	Review of Severity Rating Scales for Restless Legs Syndrome: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 317-324.	0.8	32
317	Non-motor symptoms: the core of multi-morbid Parkinson's disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2014, 75, 18-24.	0.2	38
318	Cortical Thickness, Surface Area and Volume Measures in Parkinson's Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. <i>PLoS ONE</i> , 2014, 9, e114167.	1.1	45
319	Review of Diagnostic Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 1343-1349.	1.4	47
320	Multi-domain Scales. , 2014, , 13-23.		2
321	Comprehensive Non-motor Symptoms Assessments. , 2014, , 43-47.		0
322	Phenomenology of Levodopa-Induced Dyskinesia. , 2014, , 1-16.		1
323	Scales for Measuring Parkinsonism in Demented Patients. , 2014, , 117-128.		0
324	Scales that Evaluate Specific Non-motor Disorders. , 2014, , 49-65.		2

#	ARTICLE	IF	CITATIONS
325	Parkinson's disease and vision. <i>Basal Ganglia</i> , 2013, 3, 159-163.	0.3	23
326	Daytime apomorphine infusion combined with transdermal Rotigotine patch therapy is tolerated at 2 years: A 24-h treatment option in Parkinson's disease. <i>Basal Ganglia</i> , 2013, 3, 127-130.	0.3	13
327	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. <i>Journal of Neurology</i> , 2013, 260, 2701-2714.	1.8	128
328	Symptom prevalence, severity and palliative care needs assessment using the Palliative Outcome Scale: A cross-sectional study of patients with Parkinson's disease and related neurological conditions. <i>Palliative Medicine</i> , 2013, 27, 722-731.	1.3	77
329	Unveiling relevant non-motor Parkinson's disease severity symptoms using a machine learning approach. <i>Artificial Intelligence in Medicine</i> , 2013, 58, 195-202.	3.8	50
330	Oropharyngeal dysphagia in Parkinson's disease: Comments on paper by Kalf et al.. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 275.	1.1	2
331	Nonmotor fluctuations in Parkinson disease. <i>Neurology</i> , 2013, 80, 800-809.	1.5	284
332	Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?. <i>Journal of Neural Transmission</i> , 2013, 120, 1305-1320.	1.4	87
333	Microglia, Amyloid, and Glucose Metabolism in Parkinson's Disease with and without Dementia. <i>Neuropsychopharmacology</i> , 2013, 38, 938-949.	2.8	202
334	Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 660-665.	1.1	112
335	The impact of deep brain stimulation on the nonmotor symptoms of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 639-642.	1.4	23
336	Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 1073-1078.	1.1	43
337	Managing impulse control behaviours in Parkinson's disease: practical guidelines. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013, 74, 160-166.	0.2	14
338	The Role of Self-Awareness and Cognitive Dysfunction in Parkinson's Disease With and Without Impulse-Control Disorder. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, 141-149.	0.9	29
339	Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. <i>Neurology</i> , 2013, 80, 792-799.	1.5	163
340	Impulse control disorders and related behaviors. , 2013, , 140-152.		3
341	Neuropsychiatric and cognitive disorders in other parkinsonian disorders. , 2013, , 261-274.		3
342	Neuropsychiatric aspects of the on/off phenomenon. , 2013, , 275-284.		1

#	ARTICLE	IF	CITATIONS
343	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. PLoS ONE, 2013, 8, e57221.	1.1	95
344	Morning Akinesia and the Potential Role of Gastroparesis – Managing Delayed Onset of First Daily Dose of Oral Levodopa in Patients with Parkinson’s Disease. European Neurological Review, 2013, 8, 82.	0.5	14
345	Sleep dysfunction. , 2013, , 120-143.		0
346	Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease. Clinical Neuropharmacology, 2012, 35, 205-207.	0.2	51
347	Career mentorship for young neurologists in Europe. Neurology, 2012, 79, 381-383.	1.5	0
348	2.135 CHARACTERISING NON MOTOR PATTERNS OF EARLY MORNING OFF PERIODS IN PARKINSON'S DISEASE: AN INTERNATIONAL STUDY. Parkinsonism and Related Disorders, 2012, 18, S110.	1.1	2
349	Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease. Journal of Neurology, 2012, 259, 1639-1647.	1.8	211
350	Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson’s disease: Results from a 1-year, open-label extension of the RECOVER study. Basal Ganglia, 2012, 2, 79-85.	0.3	20
351	[18F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [18F]FDOPA and [11C]DASB PET study in Parkinson's disease. NeuroImage, 2012, 59, 1080-1084.	2.1	54
352	Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. European Journal of Neurology, 2012, 19, 105-113.	1.7	84
353	Symptoms and Quality of Life in Late Stage Parkinson Syndromes: A Longitudinal Community Study of Predictive Factors. PLoS ONE, 2012, 7, e46327.	1.1	83
354	Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. American Journal of Neurodegenerative Disease, 2012, 1, 160-7.	0.1	24
355	Excessive Daytime Sleepiness in Patients with Parkinson’s Disease. CNS Drugs, 2011, 25, 203-212.	2.7	101
356	Changes in the non-motor symptom scale in Parkinson’s disease after deep brain stimulation. Basal Ganglia, 2011, 1, 131-133.	0.3	17
357	Reversible acute worsening of motor and non-motor symptoms in advanced Parkinson’s disease after long distance travels. Basal Ganglia, 2011, 1, 231-232.	0.3	0
358	Handbook of Non-Motor Symptoms in Parkinson's Disease. , 2011, , .		6
359	Parkinson’s disease: The non-motor issues. Parkinsonism and Related Disorders, 2011, 17, 717-723.	1.1	313
360	Other Symptoms. , 2011, , 91-97.		0

#	ARTICLE	IF	CITATIONS
361	Sensory Symptoms. , 2011, , 73-77.		1
362	The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project. Parkinson's Disease, 2011, 2011, 1-7.	0.6	13
363	Nonmotor Symptoms of Parkinson's Disease. Parkinson's Disease, 2011, 2011, 1-2.	0.6	1
364	A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK. Journal of Medical Economics, 2011, 14, 584-593.	1.0	37
365	Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurology, 2011, 11, 28.	0.8	112
366	Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). Movement Disorders, 2011, 26, 90-99.	2.2	394
367	The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Movement Disorders, 2011, 26, 399-406.	2.2	744
368	Parkinson's disease sleep scale validation of the revised version PDSS-2. Movement Disorders, 2011, 26, 644-652.	2.2	296
369	Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect. Journal of Parkinson's Disease, 2011, 1, 197-203.	1.5	107
370	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. Movement Disorders, 2010, 25, 704-709.	2.2	342
371	Parkinson's disease symptoms: The patient's perspective. Movement Disorders, 2010, 25, 1646-1651.	2.2	464
372	The challenge of non-motor symptoms in Parkinson's disease. Progress in Brain Research, 2010, 184, 325-341.	0.9	142
373	Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain, 2010, 133, 3434-3443.	3.7	273
374	Narcolepsy in Parkinson's disease. Expert Review of Neurotherapeutics, 2010, 10, 879-884.	1.4	28
375	Oral and Infusion Levodopa-Based Strategies for Managing Motor Complications in Patients with Parkinson's Disease. CNS Drugs, 2010, 24, 119-129.	2.7	60
376	Practice Parameter: Treatment of nonmotor symptoms of Parkinson disease [RETIRED]. Neurology, 2010, 74, 924-931.	1.5	253
377	Parkinsonian syndromes. , 2010, , 33-47.		0
378	International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology, 2009, 73, 1584-1591.	1.5	213

#	ARTICLE	IF	CITATIONS
379	Handbook of Movement Disorders. , 2009, , .		2
380	REM sleep behavior disorder and the risk of developing Parkinson disease or dementia. Neurology, 2009, 72, 1294-1295.	1.5	19
381	Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurology, The, 2009, 8, 464-474.	4.9	1,367
382	Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3-year European multicenter study with repeat [¹²³ I]FP-CIT SPECT. Movement Disorders, 2009, 24, 500-508.	2.2	195
383	Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation—Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Movement Disorders, 2009, 24, 635-646.	2.2	147
384	Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders, 2009, 24, 1468-1474.	2.2	233
385	The dopaminergic basis of sleep dysfunction and non motor symptoms of Parkinson's disease: Evidence from functional imaging. Experimental Neurology, 2009, 216, 247-248.	2.0	15
386	Psychometric properties of the Parkinson's Disease Sleep Scale — Brazilian version. Parkinsonism and Related Disorders, 2009, 15, 495-499.	1.1	29
387	Sleep dysfunction and role of dysautonomia in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S93-S95.	1.1	13
388	Dopamine receptor agonists and sleep disturbances in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S101-S104.	1.1	31
389	Early Parkinson's disease and non-motor issues. Journal of Neurology, 2008, 255, 33-38.	1.8	95
390	SCOPA-sleep and PDSS: Two scales for assessment of sleep disorder in Parkinson's disease. Movement Disorders, 2008, 23, 1681-1688.	2.2	80
391	Treatment and identification of restless legs syndrome. The Prescriber, 2008, 19, 56-59.	0.1	2
392	Health-related quality of life in Asian and other ethnic groups with Parkinson's disease. European Journal of Neurology, 2008, 15, 642-642.	1.7	2
393	Quantitation of non-motor symptoms in Parkinson's disease. European Journal of Neurology, 2008, 15, 2-8.	1.7	154
394	Clinical risk-benefit assessment of dopamine agonists. European Journal of Neurology, 2008, 15, 15-23.	1.7	24
395	Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2008, 7, 595-604.	4.9	195
396	Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo-controlled trial. Sleep Medicine, 2008, 9, 874-881.	0.8	84

#	ARTICLE	IF	CITATIONS
397	Patterns of treatment for restless legs syndrome in primary care in the United Kingdom. <i>Clinical Therapeutics</i> , 2008, 30, 405-418.	1.1	3
398	Crystallisation within transdermal rotigotine patch: is there cause for concern?. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 1169-1171.	2.4	49
399	Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 948-951.	0.9	109
400	Sleep and Quality of Life in Parkinson's Disease. , 2008, , 175-185.		4
401	Non-motor symptoms: Identification and management. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S450-S456.	1.1	48
402	Infectious basis to the pathogenesis of Parkinson's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 373-384.	1.0	0
403	Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Delivery</i> , 2007, 4, 111-118.	2.4	21
404	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. <i>Movement Disorders</i> , 2007, 22, 1623-1629.	2.2	461
405	The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. <i>Movement Disorders</i> , 2007, 22, 1901-1911.	2.2	838
406	Clinical significance of RLS. <i>Movement Disorders</i> , 2007, 22, S395-S400.	2.2	40
407	Rotigotine: first dopamine agonist transdermal patch. <i>The Prescriber</i> , 2007, 18, 19-30.	0.1	2
408	Nature and variants of idiopathic restless legs syndrome: observations from 152 patients referred to secondary care in the UK. <i>Journal of Neural Transmission</i> , 2007, 114, 929-934.	1.4	37
409	Sleep-related problems of Parkinson's disease. <i>Age and Ageing</i> , 2006, 35, 220-228.	0.7	140
410	The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. <i>Journal of the Neurological Sciences</i> , 2006, 248, 158-162.	0.3	99
411	Iron and restless legs syndrome: The story unfolds. <i>Sleep Medicine</i> , 2006, 7, 395-396.	0.8	6
412	Non-motor symptoms of Parkinson's disease: diagnosis and management. <i>Lancet Neurology</i> , The, 2006, 5, 235-245.	4.9	2,202
413	International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. <i>Movement Disorders</i> , 2006, 21, 916-923.	2.2	865
414	Myasthenia gravis—a rare presentation with tongue atrophy and fasciculation. <i>Age and Ageing</i> , 2006, 35, 87-88.	0.7	14

#	ARTICLE	IF	CITATIONS
415	Non-motor symptoms in Parkinson's disease: an underdiagnosed problem. <i>Aging Health</i> , 2006, 2, 967-982.	0.3	19
416	A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 465-469.	0.9	130
417	Genetic aspects of restless legs syndrome. <i>Postgraduate Medical Journal</i> , 2006, 82, 626-629.	0.9	13
418	Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI. <i>Neurology</i> , 2006, 67, 2199-2205.	1.5	137
419	Management of bladder dysfunction in patients with multiple-system atrophy. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 652-653.	2.7	0
420	Restless legs syndrome: diagnosis and review of management options. <i>Neuropsychiatric Disease and Treatment</i> , 2006, 2, 155-164.	1.0	19
421	Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. <i>Journal of Neural Transmission</i> , 2005, 112, 661-668.	1.4	42
422	The non-motor symptom complex of Parkinson's disease: A comprehensive assessment is essential. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 275-283.	2.0	203
423	Behavioural and Psychiatric Symptoms in Patients With Neurodegenerative Diseases. <i>Brain Impairment</i> , 2005, 6, 181-190.	0.5	0
424	Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 115-117.	0.9	95
425	Diagnosing restless legs syndrome (RLS) in primary care. <i>Current Medical Research and Opinion</i> , 2004, 20, 1785-1795.	0.9	32
426	Parkinson's disease sleep scale: Validation study of a Spanish version. <i>Movement Disorders</i> , 2004, 19, 1226-1232.	2.2	44
427	Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. <i>Movement Disorders</i> , 2004, 19, 1522-1523.	2.2	40
428	Dopamine agonist switching in Parkinson's disease. <i>British Journal of Hospital Medicine</i> , 2004, 65, 215-219.	0.3	13
429	Clinical assessment of nocturnal disability in Parkinson's disease. <i>Neurology</i> , 2004, 63, S17-20.	1.5	36
430	The restless legs syndrome. <i>Practical Neurology</i> , 2003, 3, 204-213.	0.5	14
431	Restless Legs Syndrome. <i>New England Journal of Medicine</i> , 2003, 349, 815-815.	13.9	4
432	Nocturnal symptom complex in PD and its management. <i>Neurology</i> , 2003, 61, S17-23.	1.5	61

#	ARTICLE	IF	CITATIONS
433	Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert Opinion on Pharmacotherapy, 2002, 3, 1481-1487.	0.9	12
434	The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 629-635.	0.9	543
435	A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 246-249.	0.9	61
436	???Sleep Attacks??? or ???Unintended Sleep Episodes??? Occur with Dopamine Agonists. Drug Safety, 2002, 25, 473-483.	1.4	46
437	The frequency and significance of â€˜striatal toeâ€™™ in parkinsonism. Parkinsonism and Related Disorders, 2002, 9, 97-101.	1.1	21
438	Restless legs syndrome (RLS), Parkinson's disease, and sustained dopaminergic therapy for RLS. Sleep Medicine, 2002, 3, S51-S55.	0.8	13
439	An imaging study of parkinsonism among African-Caribbean and Indian London communities. Movement Disorders, 2002, 17, 1321-1328.	2.2	15
440	Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure: a case report. Clinical Autonomic Research, 2002, 12, 203-206.	1.4	15
441	Serum prolactin levels in Parkinson's disease and multiple system atrophy. Clinical Autonomic Research, 2002, 12, 393-398.	1.4	20
442	The basis for day and night-time control of symptoms of Parkinson's disease. European Journal of Neurology, 2002, 9, 40-43.	1.7	16
443	Sustained Dopamine Agonism with Cabergoline in Parkinsonâ€™™s Disease. Advances in Behavioral Biology, 2002, , 379-384.	0.2	0
444	Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist. International Journal of Clinical Practice, 2002, 56, 468-74.	0.8	7
445	Autonomic dysfunction in movement disorders. Current Opinion in Neurology, 2001, 14, 505-511.	1.8	73
446	MRI changes in multiple sclerosis following treatment with lofepramine and l-phenylalanine. NeuroReport, 2001, 12, 1821-1824.	0.6	30
447	Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. Journal of Neural Transmission, 2001, 108, 571-580.	1.4	72
448	A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. Journal of Neural Transmission, 2001, 108, 71-77.	1.4	104
449	Phenotypic and neuropathologic heterogeneity of anti-Hu antibody-related paraneoplastic syndrome presenting with progressive dysautonomia: report of two cases. Clinical Autonomic Research, 2001, 11, 115-118.	1.4	24
450	Erythropoietin deficiency and anaemia in multiple system atrophy. Movement Disorders, 2001, 16, 233-239.	2.2	37

#	ARTICLE	IF	CITATIONS
451	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. <i>Movement Disorders</i> , 2001, 16, 197-201.	2.2	111
452	Achieving 24-Hour Control of Parkinson's Disease Symptoms: Use of Objective Measures to Improve Nocturnal Disability. <i>European Neurology</i> , 2001, 46, 3-10.	0.6	33
453	Cervical dystonia is associated with a polymorphism in the dopamine (D5) receptor gene. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 262-264.	0.9	50
454	Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders. <i>Archives of Neurology</i> , 2001, 58, 259.	4.9	375
455	Restless legs syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 143-146.	0.9	41
456	Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK. <i>Movement Disorders</i> , 2000, 15, 18-23.	2.2	78
457	Parkinson's disease misdiagnosed as multiple system atrophy by sphincter electromyography. <i>Journal of Neurology</i> , 2000, 247, 559-561.	1.8	27
458	Cortical dysfunction in non-demented Parkinson's disease patients: A combined 31P-MRS and 18FDG-PET study. <i>Brain</i> , 2000, 123, 340-352.	3.7	214
459	Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 238-241.	0.9	78
460	Erythropoietin depletion and anaemia in diabetes mellitus. <i>Diabetic Medicine</i> , 1999, 16, 813-819.	1.2	109
461	Limb contractures in levodopa-responsive parkinsonism: a clinical and investigational study of seven new cases. <i>Journal of Neurology</i> , 1999, 246, 671-676.	1.8	31
462	Progression of falls in postmortem-confirmed Parkinsonian disorders. <i>Movement Disorders</i> , 1999, 14, 947-950.	2.2	144
463	Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. <i>Acta Neurologica Scandinavica</i> , 1999, 100, 163-167.	1.0	135
464	ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 1999, 246, s001-s005.	1.8	0
465	Repetitive belching, aerophagia, and torticollis in Huntington's disease: A case report. <i>Movement Disorders</i> , 1998, 13, 363-365.	2.2	29
466	Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. <i>Journal of Neural Transmission</i> , 1998, 105, 217-227.	1.4	53
467	Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. <i>European Journal of Neurology</i> , 1998, 5, 451-457.	1.7	36
468	Is EEG useful in the differential diagnosis of parkinsonism?. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 79-80.	1.1	5

#	ARTICLE	IF	CITATIONS
469	Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies. Archives of Neurology, 1998, 55, 969.	4.9	325
470	Subcutaneous apomorphine in Parkinson's disease. BMJ: British Medical Journal, 1998, 316, 641-641.	2.4	23
471	How far are we in understanding the cause of Parkinson's disease?. Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 104-104.	0.9	1
472	What Is the Accuracy of the Clinical Diagnosis of Multiple System Atrophy?. Archives of Neurology, 1997, 54, 937.	4.9	222
473	Accuracy of the Clinical Diagnosis of Corticobasal Degeneration. Neurology, 1997, 48, 119-125.	1.5	436
474	Spontaneous dissections of the internal carotid artery: appearances on colour Doppler ultrasound.. British Journal of Radiology, 1997, 70, 50-57.	1.0	23
475	Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism and Related Disorders, 1997, 3, 103-107.	1.1	58
476	Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.7	148
477	Postprandial hypotension and parkinsonian state in parkinson's disease. Movement Disorders, 1997, 12, 877-884.	2.2	55
478	Unilateral abdominal muscle herniation with pain: a distinctive variant of diabetic radiculopathy. , 1997, 14, 803-807.		27
479	The neurology of diabetes. British Journal of Hospital Medicine, 1997, 58, 343-7.	0.0	0
480	Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology, 1996, 46, 922-930.	1.5	441
481	Proton magnetic resonance spectroscopy of the striatum in Parkinson's disease patients with motor response fluctuations. Parkinsonism and Related Disorders, 1996, 2, 63-67.	1.1	17
482	No Association between Parkinson's Disease and Low-Activity Alleles of CatecholO-Methyltransferase. Biochemical and Biophysical Research Communications, 1996, 228, 780-784.	1.0	83
483	Human immunodeficiency virus-related progressive multifocal leukoencephalopathy presenting with an akinetic rigid syndrome. Movement Disorders, 1996, 11, 758-761.	2.2	8
484	Parkinson's Disease in Populations of African Origin A Review. Neuroepidemiology, 1996, 15, 214-221.	1.1	28
485	Central defects of autonomic function in secondary progressive multiple sclerosis: observations based on cardiovascular and growth hormone responses to clonidine. European Journal of Neurology, 1995, 2, 163-169.	1.7	2
486	Magnetic resonance spectroscopic study of parkinsonism related to boxing.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 561-562.	0.9	5

#	ARTICLE	IF	CITATIONS
487	Two novel mutations in the gene for copper zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 1995, 4, 1239-1240.	1.4	54
488	The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: A clinicopathological study. <i>Journal of the Neurological Sciences</i> , 1995, 129, 11-12.	0.3	57
489	Octreotide reduces alcohol-induced hypotension and orthostatic symptoms in primary autonomic failure. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1995, 88, 719-25.	0.2	1
490	Hemiplegia in Pregnancy due to Metastatic Cerebral Angiosarcoma. <i>European Neurology</i> , 1994, 34, 295-297.	0.6	8
491	Motor neuron disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 886-896.	0.9	163
492	Expression of β_2 -Adrenoceptors on Circulating Mononuclear Cells in Hypertensives and Normotensives Before and After Reduction of Central Sympathetic Outflow by Clonidine. <i>Blood Pressure</i> , 1994, 3, 172-177.	0.7	9
493	Fourth meeting of the European Neurological Society 25 th -29 June 1994 Barcelona, Spain. <i>Journal of Neurology</i> , 1994, 241, 1-164.	1.8	20
494	The relationship between blood flow and pulsatility index in the superior mesenteric artery at rest and during constrictor stimuli in normal subjects. <i>Journal of Clinical Ultrasound</i> , 1994, 22, 149-160.	0.4	18
495	Carpopedal Spasm as Presenting Feature of Adult Moyamoya Disease. <i>Cerebrovascular Diseases</i> , 1994, 4, 106-107.	0.8	1
496	Physiological assessment of aspects of autonomic function in patients with secondary progressive multiple sclerosis. <i>Journal of Neurology</i> , 1993, 240, 139-143.	1.8	68
497	Alcohol ingestion lowers supine blood pressure, causes splanchnic vasodilatation and worsens postural hypotension in primary autonomic failure. <i>Journal of Neurology</i> , 1993, 241, 145-152.	1.8	29
498	The effect of captopril on the superior mesenteric artery and portal venous blood flow in normal man.. <i>British Journal of Clinical Pharmacology</i> , 1993, 35, 517-524.	1.1	14
499	Effects of Oral Alcohol on Superior Mesenteric Artery Blood Flow in Normal Man, Horizontal and Tilted. <i>Clinical Science</i> , 1993, 84, 419-425.	1.8	20
500	Cardiovascular and hormonal responses to liquid food challenge in idiopathic Parkinson's disease, multiple system atrophy, and pure autonomic failure. <i>Neurology</i> , 1993, 43, 900-900.	1.5	35
501	Differential responses in superior mesenteric artery blood flow may explain the variant pressor responses to clonidine in two groups with sympathetic denervation. <i>Clinical Science</i> , 1992, 83, 59-64.	1.8	12
502	Abnormality of superior mesenteric artery blood flow responses in human sympathetic failure.. <i>Journal of Physiology</i> , 1992, 457, 477-489.	1.3	56
503	Growth hormone response to clonidine in central and peripheral primary autonomic failure. <i>Lancet</i> , 1992, 340, 263-266.	6.3	48
504	Thermal Thresholds and Motor Sensory Conduction Measurements in Guillain Barré Syndrome: 12-Month Follow-Up Study. <i>European Neurology</i> , 1992, 32, 274-280.	0.6	6

#	ARTICLE	IF	CITATIONS
505	Study of EEGs following 24-Hour Sleep Deprivation in Patients with Posttraumatic Epilepsy. European Neurology, 1992, 32, 79-82.	0.6	15
506	Noninvasive quantification of superior mesenteric artery blood flow during sympathoneural activation in normal subjects. Clinical Autonomic Research, 1991, 1, 37-42.	1.4	43
507	Value of non-invasive continuous blood pressure monitoring in the detection of carotid sinus hypersensitivity. Clinical Autonomic Research, 1991, 1, 157-159.	1.4	17
508	Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.. Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 372-373.	0.9	26
509	A CASE OF SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTING AS GUILLAIN-BARRÉ% SYNDROME. Rheumatology, 1989, 28, 440-442.	0.9	36
510	SLIBCUTANEOUS APOMORPHINE FOR ON-OFF OSCILLATIONS IN PARKINSON'S DISEASE. Lancet, The, 1988, 332, 1260.	6.3	66
511	Effect of PGF 2 alpha and stress on the ascorbic acid content of rat adrenal gland (a histochemical) Tj ETQq1 1 0.784314 rgBT ₀ /Overlock	0.2	0
512	Parkinsonâ€™s disease: pathology, anatomy, and behavior. , 0, , 14-24.		0
513	The boundaries of Parkinsonâ€™s disease dementia and dementia with Lewy bodies. , 0, , 40-52.		0
514	Clinical assessment: mood and motivation. , 0, , 65-72.		0
515	Imaging and behavior in Parkinsonâ€™s disease: structural imaging. , 0, , 73-88.		0
516	Imaging and behavior in Parkinsonâ€™s disease: functional imaging. , 0, , 89-96.		0
517	Diagnosis and biomarkers: CSF. , 0, , 97-108.		0
518	Apathy. , 0, , 131-139.		0
519	Early cognitive impairment. , 0, , 163-176.		1
520	Parkinsonâ€™s disease dementia. , 0, , 177-191.		0
521	Sleep disturbances. , 0, , 192-210.		0
522	Surgical treatment and behavior. , 0, , 230-243.		0

#	ARTICLE	IF	CITATIONS
523	Clinical trials for psychotropic agents in Parkinson's disease using psychosis as a model. , 0, , 244-254.		0
524	Treatment of neuropsychiatric disturbances in Parkinson's disease: future prospects and strategies. , 0, , 285-291.		0
525	The genetics of behavior and cognition in Parkinson's disease. , 0, , 25-39.		0